BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Opus Genetics\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Opus Genetics\, Inc.'s drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05616793-10884@assetmemo.bio
DTSTAMP:20261121T005424Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:OPGx-LCA5: Phase 1/2 readout est. (NCT05616793)
DESCRIPTION:OPGx-LCA5\, phase 1/2\, Leber Congenital Amaurosis.\nStudy: Saf
 ety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Ret
 inal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Pat
 ients\nEstimated primary completion: 15 June 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/opgx-lca5#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05616793
URL:https://assetmemo.bio/drug/opgx-lca5#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
